← Back to Search
Effect Of Hyperthermic Intrathoracic Chemotherapy On The Malignant Pleural Mesothelioma: A Systematic Review And Meta-analysis
Z. Zhao, S. Zhao, M. Ren, Z. Liu, Z. Li, L. Yang
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Surgery-based multimodality therapies have been used to control the malignant effusion and its recurrence in malignant pleural mesothelioma (MPM). Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in the treatment of malignant pleural mesothelioma, but the results were controversial. The aim of the current study was, therefore, to conduct a systematic review and meta-analysis on the effect of HITHOC on MPM therapy. After thorough searching of online databases, total 21 articles were included into qualitative systematic review and 5 of them were used to conduct qualitative meta-analysis. It was found that most of HITHOC was used in combination of surgical resection including extrapleural pneumonectomy or pleurectomy/decortication. Patients who received HITHOC had significantly longer median survival length compared to the patients without HITHOC (Hedges’s g = 0.384 ± 0.105, 95% CI: 0.178∼0.591, P < 0.001). In addition, HITHOC as palliative therapy was favored (Hedges’s g = 0.591 ± 0.201, 95% CI: 0.196∼0.967, P < 0.001) in terms of recurrence free interval. The findings of the current study suggested that HITHOC is one of the safe and effective therapies in prolonging patients’ median survival time and extending recurrence free interval.
This paper references
Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases.
D. Elias (2014)
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
Hyperthermic pleural perfusion with cisplatin
A. Yellin (2001)
Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy
H. Ishibashi (2015)
Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies
O. Monneuse (2003)
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
Hongqiang Xia (2006)
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
D. Elias (2010)
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis.
Y. Matsuzaki (2004)
Anaesthetic management of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy perfusion
C. Kerscher (2014)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC)
L. Liu (2016)
Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication
P. Sugarbaker (2012)
The treatment of malignancy by hyperthermia.
C. Christophi (1998)
Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies.
A. Işık (2013)
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution’s Experience
J. Sandick (2008)
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
E. de Bree (2002)
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest
E de Bree (2002)
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
M. Migliore (2015)
Hyperthermic intraperitoneal chemotherapy: Rationale and technique.
S. González-Moreno (2010)
Safety and efficacy of thrombolytic therapy for superior vena cava syndrome.
B. Gray (1991)
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2011)
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies
M. Ried (2013)
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma
S. van Ruth (2003)
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
L. Lang-Lazdunski (2015)
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
M. Migliore (2015)
Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
P. Sugarbaker (2007)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy†.
M. Ambrogi (2016)
Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion
Mingchen Ba (2013)
This paper is referenced by
Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie
H. Hofmann (2019)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies—Experience from Indian Centers
M. D. Patel (2018)
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer
S. H. Dho (2018)
Expertenempfehlung zur Anwendung der hyperthermen intrathorakalen Chemotherapie (HITOC) in Deutschland
Michael Ried (2020)
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Fabio Nicolini (2019)
Intraoperative hypertherme intrathorakale Chemotherapie
T. Markowiak (2018)
Intratumoral hyperthermic chemotherapy injection in peripheral non-small cell lung cancer
Mohamed Tohlob (2020)